Business

Cadila Pharmaceuticals Launches Avastin Biosimilar in India

July 24th 2020

By Skylar Jeremias

Cadila Pharmaceuticals has launched a bevacizumab biosimilar referencing Avastin in India. Bevacizumab is used for the treatment of colorectal, breast, and lung cancers, among others.

Biocon Reports Strong Quarter for Its Biosimilars Unit

July 24th 2020

By Tony Hagen

For Biocon, overall revenues were up during the fiscal quarter that just ended, driven by strong revenues in its biosimilars and generics operations.

Biogen Biosimilar Revenues Dip Amid COVID-19 Pandemic

July 23rd 2020

By Tony Hagen

The company saw a 7% decline in biosimilar revenues in the second quarter of 2020 compared with the same quarter in 2019.

Bio-Thera Solutions Targets Russia for Golimumab Biosimilar

July 23rd 2020

By Skylar Jeremias

China-based Bio-Thera Solutions is breaking into the growing Russian biosimilar market by licensing the marketing rights for its unapproved golimumab biosimilar to Russian biopharmaceutical company Pharmapark.

Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation

July 22nd 2020

By Tony Hagen

Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 22nd 2020

A panel of experts discusses the ways in which payers restrict prescribing choices for physicians and what that means for the future of biosimilar utilization.

Rathore Discusses Study on Biosimilar Application Failures

July 22nd 2020

The Center for Biosimilars® interviewed Anurag S. Rathore, PhD, whose team of investigators evaluated why applications for biosimilar approvals do not succeed. Large companies as well as small find the approval process challenging, but there is a learning curve that may be followed by more consistent approvals, he explains.

Webinar: Choice Is Vital to Biosimilar Savings Picture

July 21st 2020

By Tony Hagen

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars.

New Battleground Shaping Up Over Insulin Deliverables

July 20th 2020

By Tony Hagen

With insulin originator product patents expiring, drug companies are seeking to extend exclusivities via patents on injectors and other delivery products.

World's First Halal Biosimilar to Be Produced in Malaysia

July 20th 2020

By Tony Hagen

As part of a project to build the first biosimilar factory in Malaysia, one of the initial products would be halal certified.